MitoStem, previously doing business as TechTown Ventures, had been focused on development of novel technologies to advance stem cell research and the field of regenerative medicine. Stem cells have the ability to reproduce themselves (self-renew) or differentiate into each of the cell types found in the body. In the future, Pluripotent Stem Cells (PSC) will be able to replace diseased and damaged organs. Until recently, only stem cells derived from embryos were pluripotent. However, controversies are associated with using cells from embryos, and they can only be used for study of diseases that are diagnosed during assisted reproduction procedures (in vitro fertilization). Mitostem is working to develop and commercialize a protein transduction technology, which will make the generation of iPSC's more practical, simple and affordable
